theMednetRegister

Nephrology

Glomerulonephritis   

Questions discussed in this category

What is your treatment approach when managing patients with relapsing lupus nephritis who previously achieved remission with mycophenolate and steroids?
5 Answers available
Under what circumstances would you consider obinutuzumab instead of rituximab when treating primary membranous nephropathy?
Hu et al., PMID 39207845
1 Answer available
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
1 Answer available
In which patients with MGUS do you recommend a kidney biopsy to evaluate for MGRS?
2 Answers available
What are some indications that might lead you to pursue a kidney biopsy in a patient with presumed diabetic kidney disease?
3 Answers available
Do you ever combine voclosporin and belimumab in the treatment of lupus nephritis?
Do you use them sequentially or together?
3 Answers available
How do you approach the management of patients with suspected membranous lupus nephritis who are found to have positive PLA2R antibodies?
1 Answer available
What are your top takeaways from ASN 2024?
1 Answer available
How would you manage a patient with CKD4 due to lupus nephritis of unknown class who develops AKI requiring hemodialysis and nephrotic range proteinuria and is found to have atrophic kidneys on imaging?
3 Answers available
How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?
Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.
1 Answer available
What is your approach for steroid dosing for patients with ANCA vasculitis on induction treatment with rituximab, avacopan, and glucocorticoid therapy?
1 Answer available
What are your management strategies for patients with biopsy proven IgA nephropathy with rapidly progressive glomerulonephritis?
2 Answers available
Do you prefer starting a SGLT2i before steroids in patients with IgA nephropathy and proteinuria > 1.0 gram/day who are unable to tolerate ACEi/ARB due to hypotension?
1 Answer available
Do you routinely obtain serum anti-THSD7A and anti-NELL1 tests in your patients with nephrotic syndrome suspected secondary to membraneous nephropathy?
1 Answer available
Do you assess for podocyte detachment in addition to effacement when considering the degree of glomerular injury and potential treatment options following a native kidney biopsy in a patient with proteinuria?
1 Answer available
What is your approach to immunosuppression in patients with preserved kidney function who are found to have nephrotic syndrome of unknown etiology and cannot safely undergo a kidney biopsy?
1 Answer available
How do you manage a pregnant patient with lupus who develops renal disease during pregnancy that is not due to pre-eclampsia?
2 Answers available
Are there instances when you would recommend obtaining a 24 hour urine protein measurement in place of spot urine protein studies in patients with acute kidney injury and proteinuria?
2 Answers available
Would you use voclosporin or belimumab as adjunctive therapy for treatment of lupus nephritis?
How does the presence of extra-renal manifestations influence this decision?
8 Answers available
What is your threshold to repeat a kidney biopsy in a patient with a history of lupus nephritis who is on maintenance therapy and develops subtle changes in urinary protein excretion or microscopic hematuria?
3 Answers available
What drives you to choose voclospsorin over tacrolimus given the substantially higher cost?
2 Answers available
Would you recommend genetic testing to determine if there is a potential underlying primary process in a patient with congenital solitary kidney who is presumed to have secondary FSGS?
1 Answer available
Do you obtain spot urine protein or 24 hour urine protein quantification studies in pregnant patients who are found to have proteinuria on a standard urinalysis test?
1 Answer available
How do you determine duration of therapy for patients who have responded well to voclosporin therapy?
How do you monitor response and what do you consider a satisfactory response? Do you aim for a certain threshold of proteinuria?
3 Answers available
When would you administer the next maintenance dose of rituximab in a patient with ANCA glomerulonephritis who last received an infusion six months ago and has low immunoglobulin levels and an undetectable CD-19 cell count?
1 Answer available
What instances will you start outpatient steroids in patients with nephrotic syndrome of unknown etiology prior to obtaining a kidney biopsy?
2 Answers available
How do you approach discussing the pill burden of voclosporin with patients who already have to take a regimen such as MMF+HCQ+ACEi and possibly more?
2 Answers available
How do you choose between eculizumab and ravulizumab for patients with acute kidney injury from complement mediated thrombotic microangiopathy?
1 Answer available
How frequently do you monitor anti-PLA2R antibody titers in patients with stable renal function/proteinuria and a past diagnosis of PLA2R-associated membranous nephropathy?
1 Answer available
Are there patients with granulomatosis with polyangiitis on maintenance rituximab therapy for whom you do not co-administer glucocorticoid therapy?
1 Answer available
Do you extend the duration of maintenance therapy past 24 months for patients with ANCA glomerulonephritis who have multiple organ involvement?
2 Answers available
For patients with suspected complement-mediated TMA, are there specific clinical or laboratory parameters that can help guide the decision for starting empirical treatment (e.g., eculizumab) while awaiting the results of complement testing?
1 Answer available
Do you prefer a mycophenolate or tacrolimus based glucocorticoid-sparing regimen for patients with minimal change disease?
2 Answers available
Do you pursue a skin biopsy or kidney biopsy in patients whom you suspect have X-linked Alport syndrome?
2 Answers available
In which patients with suspected IgA nephropathy and microalbuminuria would you recommend a kidney biopsy?
1 Answer available
What else do you consider in the differential diagnosis for pulmonary-renal syndromes if there is low clinical and serologic evidence of AAV, Goodpasture's or other rheumatologic disease (SLE, RA, APS, Scleroderma)?
2 Answers available
Would you treat a patient aggressively for lupus nephritis if they have persistent proteinuria over 1 gram but cannot get a timely kidney biopsy?
3 Answers available
What would be the clinical role of SGLT-2 inhibitors for lupus nephritis given it has an indication for proteinuria related to CKD?
5 Answers available
What are some measures to prevent flares of loin pain-hematuria syndrome?
1 Answer available
When would you consider a kidney biopsy in a patient with longstanding diabetes and hypertension (baseline creatinine 4-5, 4+ proteinuria) who was recently found to have dsDNA positivity?
1 Answer available
Would you check ANCA titers in a patient with a history of PR-3-ANCA glomerulonephritis in remission and a stable creatinine but with recurrent microscopic hematuria?
6 Answers available
Are there instances when you would pursue a kidney biopsy in a pregnant patient instead of waiting to perform the procedure post-delivery?
2 Answers available
Is there a role for eculizumab in the management of refractory lupus nephritis?
3 Answers available
Do you think there would be benefit in using sparsentan over irbesartan for FSGS given a higher percentage of patients with partial remission of proteinuria on sparsentan despite no significant difference in eGFR slope in the DUPLEX Trial?
PMID 37921461
2 Answers available
Do you consider starting hydroxyurea in a patient with hemoglobin S-beta thalassemia with chronic kidney disease secondary to FSGS?
No transfusion dependence but has hemoglobin in the 8-9 g/dl range.
1 Answer available
What are your top takeaways from ASN 2023?
2 Answers available
Are there instances when you recommend obtaining more than 2 kidney cores when performing a native kidney biopsy?
2 Answers available
Is there a role for a kidney biopsy in patients diagnosed with Fabry disease through genetic testing?
2 Answers available
Would you recommend mycophenolate mofetil for patients with progressive IgA nephropathy who do not tolerate corticosteroids?
Based on the results of the MAIN trial; Hou et al., PMID: 36745456
2 Answers available
Is there a kidney length for which you would no longer recommend attempting a kidney biopsy due to safety concerns and lack of diagnostic yield?
1 Answer available
Would you recommend proceeding with a kidney biopsy for patients' with Waldenström's macroglobulinemia who have hematuria and normal kidney function?
2 Answers available
Do you recommend a kidney biopsy in a patient with myelodysplastic syndrome diagnosed two years prior who develops new onset proteinuria?
1 Answer available
What is your approach to patients with membranous glomerulonephritis who have persistently elevated PLA2R titers but largely improved proteinuria and creatinine?
1 Answer available
Do you recommend obtaining a vasculitis work up for all patients seen for chronic kidney disease who are without a kidney biopsy?
1 Answer available
How do you approach COVID-19 vaccination in those with a prior history of glomerular disease?
2 Answers available
Would you add an SGLT2 inhibitor to augment diuresis during a hospitalization in a patient with nephrotic syndrome, an eGFR above 30 mL/min/1.73m2, and refractory hypervolemia on an intravenous loop diuretic?
1 Answer available
Are there cases of glomerulonephritis where you do not perform a kidney biopsy in a patient deemed safe to undergo the procedure?
1 Answer available
When is a kidney biopsy warranted in a patient with possible scleroderma renal crisis?
1 Answer available
Do you use both rituximab and plasmapheresis in patients with recurrent primary FSGS within three months of kidney transplantation?
1 Answer available


Papers discussed in this category

Kidney international, 2019-01
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
N Engl J Med,
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Clinical journal of the American Society of Nephrology : CJASN, 2008-01
Value of a complete or partial remission in severe lupus nephritis.
Lancet, 2021 May 07
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet (London, England), 2011 Feb 04
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Arthritis & rheumatology (Hoboken, N.J.), 2023 Jul 19
Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial.
Kidney Int Rep, 2021 Oct 06
COVID-19 Vaccination and Glomerulonephritis.
Kidney360, 2023 Mar 01
COVID-19 Vaccination and New Onset Glomerular Disease: Results from the IRocGN2 International Registry.
Kidney Int, 2022 Sep 10
Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased.
Kidney360, 2021 Dec 03
COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry.
Nephrol Dial Transplant, 2022 Jul 26
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS.
Clin Kidney J, 2021 Dec 21
Clinical spectrum of gross haematuria following SARS-CoV-2 vaccination with mRNA vaccines.
Clin Exp Nephrol, 2021 Nov 13
Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan.
Kidney Int, 2021 Sep 14
COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation?
J Am Soc Nephrol, 2022 Nov 04
A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination.
J Am Soc Nephrol, 2020 Jul 17
Kidney Biopsy Findings in Patients with COVID-19.
Am J Transplant, 2021 Feb 23
Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study.
Transplantation, 2009 Aug 15
Use of rituximab in focal glomerulosclerosis relapses after renal transplantation.
Rheumatology international, 2017 Mar 03
Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.
Rheumatology (Oxford, England), 2015 Aug 27
Eculizumab as rescue therapy in severe resistant lupus nephritis.
Journal of the American Society of Nephrology : JASN, 2017-02
A Proposal for a Serology-Based Approach to Membranous Nephropathy.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2017 Mar-Apr
Biopsy of small kidneys: A safe and a useful guide to potentially treatable kidney disease.
Clinical journal of the American Society of Nephrology : CJASN, 2017 May 04
Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis.
Kidney international reports, 2021 Jan 06
Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes.
Clin J Am Soc Nephrol, 2018 Jul 6
Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 2019 Jul 19
Dysproteinemia and the Kidney: Core Curriculum 2019.
Kidney research and clinical practice, 2021 Nov 29
Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013 Jun 19
Severe lupus nephritis: the predictive value of a ≥ 50% reduction in proteinuria at 6 months.
Clinical journal of the American Society of Nephrology : CJASN, 2020 Mar 09
The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis.
Kidney international, 2021 Apr 18
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
The New England journal of medicine, 2022 Nov 04
Empagliflozin in Patients with Chronic Kidney Disease.
Lupus science & medicine, 2020 Feb 18
Prediction of prognosis and renal outcome in lupus nephritis.
N Engl J Med, 2021 Feb 18
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Lupus Sci Med, 2018
Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis.
Pediatric nephrology (Berlin, Germany), 2020 Nov 06
Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.
The Journal of molecular diagnostics : JMD, 2012 Aug 21
Skin biopsy is a practical approach for the clinical diagnosis and molecular genetic analysis of X-linked Alport's syndrome.
Annals of the rheumatic diseases, 2024 Jan 11
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2012-08
Cyclophosphamide without corticosteroids for treatment of severe systemic necrotizing vasculitis.
Current medical research and opinion, 2016-12
Corticosteroids: the knee jerk response.
Journal of immunological methods, 2020 Dec 13
Monitoring Ravulizumab effect on complement assays.
Kidney international reports, 2021 Mar 24
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
Kidney international, 2020 Mar 06
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Cancer, 2006-09-15
Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero.
Journal of the National Medical Association, 1979 Feb
Administration of cyclophosphamide during late pregnancy and early lactation: a case report.
Annals of the rheumatic diseases, 2023 Oct 12
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Kidney international, 2024 Jan
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS.
Lupus, 2023 Sep 27
Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A "post-hoc" analysis of participants in the BLISS-LN and open label extension study belonging to a single center.
Arthritis Rheumatol, 2020 Aug 4
CALIBRATE: A Phase 2 Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
Cureus, 2023 May 10
Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis.
BMJ open, 2019 Dec 16
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
Annals of the rheumatic diseases, 2024 Oct 21
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.
Journal of the American Society of Nephrology : JASN, 2009-05
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2011-12
The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation.
Annals of internal medicine, 2015 Jan 06
Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2003-07
Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide.
Arthritis and rheumatism, 2013-07
Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio.
Lupus,
Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.
Arthritis care & research, 2023 Nov 28
Reference Range of Hydroxychloroquine Blood Levels That Can Reduce Odds of Active Lupus and Prevent Flares.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023 Mar 31
The influence of repeated flares in response to therapy and prognosis in lupus nephritis.
Kidney international, 2018-07
Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.
BMC nephrology, 2019-02-14
Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.
The New England journal of medicine, 2024 Oct 26
Bi- and Monoallelic Variants and Chronic Kidney Disease in West Africans.
Atencion primaria, 1997 Sep 30
[The existing differences between adolescent girls served on a first visit in a family planning center in 2 time periods].
The New England journal of medicine, 2024 Oct 25
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2024 Oct 14
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy.

Related Topics in Nephrology

Copyright © 2024 theMednet
All Rights Reserved.